General Information of the Compound
| Compound ID |
CP0014362
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
Adenosine receptor agonist, 16
Show/Hide
|
||||||||||||||||||
| Synonyms |
Copegus
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
AA-504/07617051
C-Virin
Copegus
Copegus (TN)
Cotronak
DRG-0028
Drug: Ribavirin
ICN-1229
KS-1104
R 9644
R-964
RBI034 (2-5A antisense compound) + Ribavirin
RBV
RG-964
RTC
RTCA
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (Copegus)
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin [USAN:INN]
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
SCH 18908
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Vilona (TN)
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
ribavirin
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C8H12N4O5
|
||||||||||||||||||
| Molecular Weight |
244.207
|
||||||||||||||||||
| Canonical SMILES |
NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
IWUCXVSUMQZMFG-AFCXAGJDSA-N
|
||||||||||||||||||
| CAS |
36791-04-5
437710-49-1
66510-90-5
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT05020, Adenosine receptor A1
Protein ID: PT00840, Adenosine receptor A1
Protein ID: PT06109, Geminin
Protein ID: PT06427, Genome polyprotein
Clinical Information about the Compound
Drug 1 ( Ribavirin )
| Drug Name | Ribavirin | ||
|---|---|---|---|
| Company | Hoffmann-La Roche pharmaceutical company | ||
| Indication | |||
| Target(s) |
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
Inhibitor
|
||
Drug 2 ( Ribavirin )
| Drug Name | Ribavirin | ||
|---|---|---|---|
| Company | Hoffmann-La Roche pharmaceutical company | ||
| Indication | |||
| Target(s) | |||